Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

AltheRx Pharmaceuticals

Request full access

Privately held, clinical development company focused on advancing best-in-class compounds

Washington DC, United StatesFounded 2010Biotech & Life Sciences

About AltheRx Pharmaceuticals

AltheRx Pharmaceuticals was a privately held clinical development company established in 2010. The firm's business model centered on acquiring and advancing promising drug candidates through clinical development and subsequently forming partnerships with larger biopharmaceutical companies for commercialization.

The company's formation was driven by a strategy to in-license novel products that aligned with the team's expertise. This was exemplified by its first significant milestone in March 2011, when it acquired all assets related to Solabegron from the pharmaceutical giant GlaxoSmithKline. The executive team included Shawn O'Brien as Chief Executive Officer and Eliot Ohlstein as Chief Scientific Officer. Ohlstein previously served as a Senior Vice President at GlaxoSmithKline, bringing direct experience with the newly acquired asset.

AltheRx's primary focus was the development of Solabegron, a selective beta-3 adrenoceptor agonist. This compound was positioned as a treatment for both Overactive Bladder (OAB) and Irritable Bowel Syndrome (IBS). The mechanism of Solabegron involves relaxing the bladder's smooth muscles by stimulating beta-3 receptors. Prior to the acquisition, Phase II clinical trials had already demonstrated positive results, showing a reduction in symptoms for both OAB and IBS with a favorable tolerability profile comparable to a placebo.

In June 2015, NeXeption, a biopharmaceutical management company, formed a new entity called Velicept Therapeutics with the intention of merging with AltheRx. This strategic merger was designed to advance the development of Solabegron, particularly for the OAB market. The merger was finalized in September 2015, which led to AltheRx being effectively renamed and absorbed into Velicept Therapeutics.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
51.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC May 2013 $15M $60M Undisclosed —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

AltheRx Pharmaceuticals website traffic

Latest recorded traffic for AltheRx Pharmaceuticals is 0 monthly website visits. AltheRx Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits0 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Lyopor3D collagen scaffold for 3D cell culture, suitable for testing the behavior of a wide range of cells in their natural 3D environment Brno, Czechia Operational — $132K $528K
Evergreen TheragnosticsContract development and manufacturing of therapeutic radiopharmaceuticals Jersey City, United States Acquired
A.D.A.M.A.D.A.M. is a biotech company that targets artificial bones and tissues market, using it proprietary 3D printing technology. A.D.A.M. focuses on 3D printing of different tissues (initially bones) made of patented organic materials, which can be scala Stamford, United States Operational
AC BioscienceA clinical stage biotech company focused on novel approaches to provide more effective treatments for solid tumor cancer patients Ecublens, Switzerland Operational
Sapreme TechnologieDevelops new technologies within the field of macromolecule therapeutics such as antibody-drug conjugates and oligonucleotide-based therapeutics Driebergen-Rijsenburg, Netherlands Operational
CerecinHealthcare company that develops a novel evidence-based therapeutics, and products that aim to help people Denver, United States Operational
Skyhawk TherapeuticsA drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression Waltham, United States Operational
Onkos SurgicalSurgical oncology company that develops implants and instruments for musculoskeletal tumor patients Parsippany-Troy Hills, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

AltheRx Pharmaceuticals in the Washington DC ecosystem

Live from Dealroom

The AltheRx Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Washington DC HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about AltheRx Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AltheRx Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.